secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001171843-24-006034
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva Q3 rev $4.3B (+13% YoY); raises FY2024 guidance; Austedo $435M (+28%)
--------------------------------------------------------------------------

- Q3 revenues $4.3B (+13% USD, +15% local currency); Non-GAAP diluted EPS $0.69 vs $0.60 YoY.
- Austedo US revs $435M (+28%); AJOVY global $137M (+21% local); Uzedy US $35M, FY outlook raised to ~$100M.
- Generics up 30% US, 8% Europe, 13% Int’l Markets (local currency); biosimilar to Prolia accepted by FDA/EMA.
- FY2024 guidance raised: rev $16.1-16.5B, Adj EBITDA $4.7-5.0B, Non-GAAP EPS $2.40-2.50.
- GAAP net loss $437M from $600M goodwill impairment and $450M legal provisions; cash from ops $693M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184324006034/0001171843-24-006034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184324006034/f8k_110624.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-006034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer